This is a first-in-human to learn more about the investigational drug of NX-1607 in patients with advanced malignancies.
This study is being done to see if NX-1607 is safe and tolerated, and to find the highest does that can safely be given. The study will also look at whether NX-1607 has an effect on the cancers being studied.
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Protocol Number: 23-1337
More information available at ClinicalTrials.gov: NCT05107674
Principal Investigator